Female/male | n 58/54, median (range) |
Age at lung transplantation (years) | 49.5 (11–66) |
Age at study entry (years) | 53.5 (16–70) |
n (%) | |
Diagnosis leading to lung transplantation | |
Chronic obstructive pulmonary disease | 48 (42.0) |
Cystic fibrosis | 31 (27.7) |
Idiopathic pulmonary fibrosis | 6 (5.4) |
Pulmonary hypertension | 9 (8.0) |
Other | 18 (16.1) |
Time since lung transplantation | |
<3 months | 31 (27.7) |
3 months to 1 year | 10 (8.9) |
1–3 years | 18 (16.1) |
3–5 years | 15 (13.4) |
5–10 years | 27 (24.1) |
>10 years | 11 (9.8) |
Immunosuppressive therapy | |
Calcineurin inhibitors | 107 (96) |
Mycophenolate mofetil or azathioprine | 112 (100) |
mTOR inhibitors | 5 (4) |
Systemic corticosteroids | 110 (98) |
Bronchiolitis obliterans syndrome (BOS) stage | |
BOS 0 | 71 (63.4) |
BOS 0p | 20 (17.9) |
BOS 1 | 9 (8.0) |
BOS 2 | 3 (2.7) |
BOS 3 | 6 (5.4) |
BOS undetermined | 3 (2.7) |
mTOR, mammalian target of rapamycin.